Open roles at Basecamp Research
Latest Basecamp Research Signals
What they do
Basecamp Research has raised $140 million in a Series C funding round led by S32, with participation from Nvidia and Anthropic. This oversubscribed round will support the development of the company's Eden biological foundation models and advance its pipeline of AI-designed therapeutics, particularly focusing on in vivo cell therapy.
Why it matters
Basecamp Research is developing an AI platform that integrates proprietary biological data with advanced DNA-writing technology to create next-generation therapeutics. Their Eden models are designed to reprogram patients' cells directly within the body, aiming to simplify and enhance the efficacy of cell therapies for complex diseases like cancer and autoimmune disorders.
Traction
The company has reported encouraging preclinical results across multiple therapeutic modalities and disease areas, indicating a strong potential for its pipeline of AI-designed therapeutics. Basecamp's innovative approach leverages the world's largest proprietary genomic dataset, developed through extensive global partnerships.
Where the market is going
Basecamp Research is positioned to disrupt traditional cell therapy manufacturing processes, which are often costly and complex. By enabling in vivo modifications, they threaten established players in the biotech space and capitalize on the growing demand for personalized, AI-driven medical solutions that can address unmet patient needs.